CRT 2025

Coronary

ACS and AMI Management

Why do the Guidelines Consider Heparin to be Preferential to Bivalirudin?

Speaker(s)

• 

  Michael J. Lipinski, MD, PhD

  Interventional Cardiologist
  Cardiovascular Associates of Charlottesville
  Charlottesville, Virginia, United States

  Disclosure(s): Sanofi/Genzyme: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)